Cited by 430Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, Noel W., Armstrong, Andrew J., Thiery-Vuillemin, Antoine, Oya, Mototsugu, Shore, Neal, Loredo, Eugenia, Procopio, Giuseppe, de Menezes, Juliana, Girotto, Gustavo, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Y., Sugimoto, Mikio, Virizuela, Juan A., Emmenegger, Urban, Navratil, Jiri, Buchschacher, Gary L., Poehlein, Christian, Harrington, Elizabeth A., Desai, Chintu, Kang, Jinyu, Saad, Fred·2022·NEJM Evidence

DOI 10.1056/evidoa2200043

Open this paper in CoChat — free account

Abstract

BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting. Patients were enrolled regardless of homologous recombination repair gene mutation (HRRm) status. HRRm status was determined following enrollment by tumor tissue and circulating tumor DNA tests. Patients were randomly assigned (1:1) to receive abiraterone (1000 mg once daily) plus prednisone or prednisolone with either olaparib (300 mg twice daily) or placebo. The primary end point was imaging-based progression-free survival (ibPFS) by investigator assessment. Overall survival was among the secondary end points. RESULTS: At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001) and was consistent with blinded independent central review (hazard ratio, 0.61; 95% CI, 0.49 to 0.74). At this data cutoff, overall survival data were immature (28.6% maturity; hazard ratio, 0.86; 95% CI, 0.66 to 1.12; P=0.29). The safety profile of olaparib and abiraterone was consistent with the known safety profiles of the individual drugs. The most common adverse events in the abiraterone and olaparib arm were anemia, fatigue/asthenia, and nausea. CONCLUSIONS: At primary analysis at this first data cutoff, abiraterone combined with olaparib significantly prolonged ibPFS compared with abiraterone and placebo as first-line treatment for patients with mCRPC enrolled irrespective of HRRm status. (Funded by AstraZeneca and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; ClinicalTrials.gov number, NCT03732820.)

Integrity signals

Registry

Crossref · 10.1056/evidoa2200043

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citation
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citation
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citation
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citation
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citation

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 301–400 of 430

[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases
Bilgin, G. B., Bilgin, C., Burkett, B. J., Thorpe, M. P., Packard, A. T., Fidanli, F., Childs, D. S., Muniz, M., Orme, J. J., Quevedo, J. F., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07447-0 · Cited by 1
Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Dimitrov, G., & Popov, E. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102411 · Cited by 1
Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
Roessler, N., Miszczyk, M., Matsukawa, A., Dematteis, A., Alfarhan, A. R., Cormio, A., Alqahtani, A. S., Rajwa, P., Schuettfort, V. M., Vetterlein, M. W., et al. (2025) · European Urology Open Science · doi:10.1016/j.euros.2025.08.008 · Cited by 1
Utility of Comprehensive Cancer Genome Profiling Testing in Elderly Cancer Patients
Okuyama, H., Sakuyama, H., Tahara, Y., Tsukamoto, S., Kita, I., Nomura, K., Murakami, A., Okita, Y., Nishiuchi, T., & Tsuji, A. (2025) · Oncology · doi:10.1159/000548585 · Cited by 1
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer
Labidi, S., Jiao, B., Tam, S., Fallah, P., Salehi, A., Rajan, R., Alameldin, M., Brimo, F., Foulkes, W. D., Papadakis, A. I., et al. (2025) · Cancers · doi:10.3390/cancers17213427 · Cited by 1
M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells
Shigeta, K., Takamori, S., Ozawa, H., Haratake, N., Onishi, M., Daimon, T., Kitano, T., Bhattacharya, A., Fushimi, A., Oya, M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218320 · Cited by 1
Self-citation
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer
Chang, J. C. W., Nandakumar, S., Stopsack, K. H., Fong, C. J., Pichotta, K., Jee, J., Woo, H. J., Donoghue, M. T. A., Vasselman, S. E., Barnett, E. S., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00934 · Cited by 1
Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy
Mercinelli, C., Pavlick, D. C., Agarwal, N., Spiess, P. E., Li, R., Kamat, A. M., Grivas, P. D., Gupta, S., Maiorano, B. A., Tateo, V., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag100 · Cited by 1
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production
Murray, C. E., Ontiveros, C. O., Wentworth, J., Blinkiewicz, P., Leung, B., Bai, H., Spicer, N., Holtz, A. N., Tanner, C., Balasubramanian, A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012426 · Cited by 1
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
van den Bosch, D., van der Velden, K. J. M., Beeker, A., van den Berg, H. P., Bergman, A. M., van der Doelen, M. J., van den Eertwegh, A. J. M., Hendriks, M. P., Kerkhofs, T. M. A., van de Luijtgaarden, A. C. M., et al. (2026) · Drugs - Real World Outcomes · doi:10.1007/s40801-026-00548-8 · Cited by 1
Self-citation
Cardiovascular Complications Associated with Uro-Oncology Treatments—A Primer for the Clinician
Pena, D.-L., Ilieșiu, A.-M., Aurelian, J., Grigore, M., Hodorogea, A. S., Coriu-Georgescu, C., Weiss, E., Bădilă, E., Jinga, V., & Balahura, A.-M. (2026) · Diagnostics · doi:10.3390/diagnostics16152452 · Cited by 1
Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations
Incorvaia, L., Santini, D., Matrana, M. R., Maruzzo, M., Kopp, R. M., Antonuzzo, L., Sergio Bracarda, A., Tural, D. G., Procopio, G., Bourlon, M. T., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70679 · Cited by 1
Self-citation
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation
Camps-Fajol, C., Minguillón, J., & Surrallés, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02954-4 · Cited by 1
PROpel trial
Gaur, A. S. (2022) · Indian Journal of Urology · doi:10.4103/iju.iju_229_22 · Cited by 1
Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting
Andrif, M., Elmarrachi, H., & Ismaili, N. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100677 · Cited by 1
Novel breakthroughs in advanced prostate cancer management
Lilly, E., Sarkis, J., Mahmoud, O., Gharib, K. E., Sarkis, P., & Nemr, E. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2195166 · Cited by 1
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
Martini, A., Fallara, G., Ploussard, G., & Malavaud, B. A. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00448-5 · Cited by 1
Kombinationstherapie mit Inhibitoren der Poly(Adenosindiphosphat-Ribose)-Polymerasen (PARPi) und des Androgenrezeptorsignalweges (ARPi) beim metastasierten kastrationsrefraktären Prostatakarzinom
Grimm, M., Foller, S., & Leucht, K. (2023) · Die Urologie · doi:10.1007/s00120-023-02230-1 · Cited by 2
Prevalence of DNA-Repair Gene mutations in Mexican men with prostate cancer
García-Villa, P. C., Laisequilla, A. I., Ortega, E. P., & Versón, C. A. (2024) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2024.05.009 · Cited by 1
Avances en el manejo del cáncer de riñón, vejiga y próstata
Rojas, L., Zuluaga, J. A., & Vargas, C. A. (2023) · Medicina · doi:10.56050/01205498.2309 · Cited by 1
Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer
Tolmeijer, S. H., Boerrigter, E., van Erp, N. P., & Mehra, N. (2024) · Oncotarget · doi:10.18632/oncotarget.28599 · Cited by 1
Self-citation
Indirect Comparison of PROpel and TALAPRO ‐2 Trials Using the Shiny Method: A Comparative Analysis in Metastatic Castration‐Resistant Prostate Cancer
Yasuda, Y., Wang, Z., Yoshida, S., Chen, W., Tanaka, H., & Fujii, Y. (2025) · International Journal of Urology · doi:10.1111/iju.70194 · Cited by 1
Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
Elias, R. M., & Antonarakis, E. S. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1279 · Cited by 1
Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study
Chen, S., Zhong, D., Yu, C., Cai, D., Wei, Q., Yang, M., Li, T., Zhu, Q., Ye, L., Wei, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70398-3 · Cited by 1
Pathophysiology of Cell Injury Journal
(2026) · Pathophysiology of Cell Injury Journal · doi:10.18081/2378-5225 · Cited by 1
Should We “PROpel” Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?
VanderWeele, D. J., & Hussain, M. (2022) · NEJM Evidence · doi:10.1056/evide2200154 · Cited by 1
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
Lambert, E., & Morgan Rouprêt, A. (2023) · European Urology · doi:10.1016/j.eururo.2023.09.012 · Cited by 1
The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer
Panzone, J. M., Rood, G. J., & Goldberg, H. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1515 · Cited by 1
Editorial: Expert opinions in genitourinary oncology
Lagos, G., El‐Deiry, W. S., & Liang Cheng, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1360223 · Cited by 1
How far does a new horizon extend for rucaparib in metastatic prostate cancer?
Karzai, F. H., Madan, R. A., & Figg, W. D. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1563 · Cited by 1
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic reviewPreprint
Naqvi, S. A. A., Anjum, M. U., Bibi, A., Khan, M. A., Khakwani, K. Z. R., He, H., Imran, M., Kazmi, S. Z., Raina, A., Cobran, E. K., et al. (2025) · medRxiv · doi:10.1101/2025.04.15.25325837 · Cited by 1
Advancing Poly (ADP-ribose) Polymerase Inhibition Strategies Beyond BRCA1/2 in Prostate Cancer
Jhan, J., & Li, J. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00922 · Cited by 1
PROpel: Good results for abiraterone plus olaparib in mCRPC
Clarke, N. W., & van den Heuvel, R. (2022) · doi:10.55788/086797e2
Self-citation
Inhibition de PARP dans le cancer de prostate métastatique : vers un meilleur ciblage ?
Mezepo, G., & Thiery-Vuillemin, A. (2022) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2022.08.031
Self-citation
Following the Narrow Path
Clarke, N. W. (2022) · European Urology · doi:10.1016/j.eururo.2022.09.027
Self-citation
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2022-0668
Data from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Quinn, Z. L., Leiby, B. E., Sonpavde, G., Choudhury, A. D., Sweeney, C. J., Einstein, D. J., Szmulewitz, R. Z., Sartor, O. A., Knudsen, K. E., Yang, E. S.-H., et al. (2023) · doi:10.1158/1078-0432.c.6532998
Use of next-generation sequencing in daily routine practice
Płużański, A., Tysarowski, A., Kawecki, M., Kucharz, J., Winiarczyk, K., & Krzakowski, M. J. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0001
Clinical aspects of prostate cancer in patients with germinal and somatic mutations in DNA homologous recombination repair genes
Stukan, А. I., Murashko, R. A., Nyushko, K. М., Semiglazova, Т. Y., Grigoryan, M. M., Zhdanov, V. S., Tovbulatova, K. R., & Mukhortov, A. A. (2023) · Cancer Urology · doi:10.17650/1726-9776-2023-19-2-75-88
RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
Thakur, N., Quazi, S., Naik, B., Jha, S. K., & Singh, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193736
Retracted
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer
Templeton, A. J., Omlin, A. G., Berthold, D., Beyer, J., Burger, I. A., Eberli, D., Engeler, D. S., Fankhauser, C. D., Fischer, S., Gillessen, S., et al. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40108
Metastasiertes kastrationsresistentes Prostatakarzinom mit Therapiesequenz (mCRPC)
Amsberg, G. V. (2023) · Springer eBooks · doi:10.1007/978-3-662-67297-6_8
Metastasiertes kastrationsresistentes Prostatakarzinom: Welche Sequenzen sind am sinnvollsten?
Horak, J., Petrausch, U., & Omlin, A. G. (2023) · Die Urologie · doi:10.1007/s00120-023-02212-3
PARP inhibitors in treating metastatic castration-resistant prostate cancer
Richter, I., Dvořák, J., Šámal, V., Bartoš, J., & Al-Samsam, S. (2023) · Urologie pro praxi · doi:10.36290/uro.2023.058
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
Juan-Fita, M. J., Anido, U., Méndez-Vidal, M. J., Sarrió, R. G., Muñoz-Langa, J., Sepúlveda-Sánchez, J. M., Mellado, B., Álvarez-Fernández, C., López, L. H., López‐Guerrero, J. A., et al. (2023) · Cancers · doi:10.3390/cancers15215223
Comment se prescrit l’olaparib dans le cancer de la prostate ?
Mathiéu, R. (2023) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2023.10.005
Reply to Lin Ding, Bin Yang, and Xudong Yao’s Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108
Fred Saad, C., del Rosario, P. M., & Clarke, N. W. (2023) · European Urology · doi:10.1016/j.eururo.2023.11.015
Self-citation
Addressing controversial areas in the management of advanced prostate cancer in Canada
Fred Saad, C., Hotte, S. J., Noonan, K. L., Malone, S. C., MORASH, C. G., Niazi, T. M., Rendon, R., Shayegan, B., Basappa, N. S., Cagiannos, I., et al. (2023) · Canadian Urological Association Journal · doi:10.5489/cuaj.8537
Systemtherapie des Prostatakarzinoms im hohen Alter
Amsberg, G. V., Busenbender, T., Tilki, D., & Bokemeyer, C. (2024) · Die Onkologie · doi:10.1007/s00761-023-01453-3
Update Prostatakarzinom
Falkenbach, F., & Maurer, T. (2024) · CME · doi:10.1007/s11298-023-3768-5
Biological Markers of Therapeutic Response in Prostate Cancer
Bumbaširević, U., & Petrović, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-51712-9_11
Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen
Peres, T., & Omlin, A. G. (2024) · Aktuelle Urologie · doi:10.1055/a-2201-6485
Prevalencia de mutaciones en genes de reparación en hombres mexicanos con cáncer de próstata
García-Villa, P. C., Laisequilla, A. I., Ortega, E. P., & Verson, C. A. (2024) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2024.03.003
Functionality of BRCA1 supports the survival of prostate cancer cells during the development of castration resistancePreprint
Sriraman, S., Virtanen, V., Kukkula, A., Toriseva, M., Rokka, A., Lumiainen, A., Ahlskog, J. K., West, G., POUTANEN, M. H., Taimen, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.19.599365
Olaparib for the treatment of metastatic prostate cancer
Čapoun, O. (2024) · Onkologie · doi:10.36290/xon.2024.032
Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No
Fred Saad, C. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.07.015 · Cited by 1
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer
Calvo, O. F., Iglesias, J. M., Casas, E. A. J., Molina-Díaz, A., Anido, U., Nebra, J. C., García-Bernardo, L., Martínez-Breijo, S., Lázaro-Quintela, M., Garcia, G. M., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03662-7
Hot issues on Chinese expert consensus of prostate cancer management
Han, S., Sheng, X., Qin, X., Wu, P., Yang, Z., Zeng, H., Liu, H., Wang, B., Zhou, Z., Song, G., et al. (2024) · UroPrecision · doi:10.1002/uro2.76
Sequenztherapie des kastrationsresistenten Prostatakarzinoms
Horak, J., & Omlin, A. G. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0719-6
El valor del medicamento desde una perspectiva social 2024
(2024) · Fundación Weber eBooks · doi:10.37666/l27-2024
Neue Therapieoptionen des kastrationsresistenten Prostatakarzinoms
Klier, J. (2024) · best practice onkologie · doi:10.1007/s11654-024-00613-0
Real-world efficacy and safety of combined first-line treatment with PARP inhibitors and novel hormonal therapy in mCRPC patients with HRR gene mutations
Guo, A., Wu, C., Cao, J., Zhu, K., & Ding, S. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1505163
Olaparib bei biochemischem Rezidiv des High-risk-Prostatakarzinoms nach Prostatektomie
Hintelmann, K., & Boeckelmann, L. (2024) · Strahlentherapie und Onkologie · doi:10.1007/s00066-024-02350-3
Incisional PSMA PET/CT-positive recurrences in prostate cancer– is there an implication on clinical care?
Mazzucato, G., Falkenbach, F., Ekrutt, J., Köehler, D., Amsberg, G. V., Cerruto, M. A., Antonelli, A., Steuber, T. P., Graefen, M., & Maurer, T. (2025) · Clinical & Experimental Metastasis · doi:10.1007/s10585-025-10331-8
Re: Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, et al. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.09.013
Yuan, S., Chen, P., Sun, F., & Li, T. (2025) · European Urology Focus · doi:10.1016/j.euf.2024.11.014
The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review
Pinto, Á., Domínguez, M., Iturriaga, A. G., Rodríguez‐Vida, A., Casas, J. A. V., & Castro, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104678
Prostate Cancer Playback: Highlights of 2024
(2025) · EMJ Urology · doi:10.33590/emjurol/iieq4765
Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification
Vázquez, S., Gallardo, E., Calvo, O. F., Juan-Fita, M. J., Pino, Á. M., Lázaro-Quintela, M., Anido, U., & del Alba, A. G. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102338
6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Busenbender, T., Pelageev, D. N., Hauschild, J., Kaune, M., Boeckelmann, L., Krisp, C., Elsesy, M. E., Zielinski, A., Mair, T., Riedner, M., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0955
FDA-approved therapeutics and diagnostics for prostate cancer
Chen, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23585-6.00002-9
Re: Gerhardt Attard, Neeraj Agarwal, Julie Graff, et al. Niraparib plus Abiraterone Acetate and Prednisone for HRR-mutated Metastatic Castration-sensitive Prostate Cancer: Results from the AMPLITUDE Phase 3 Trial. J Clin Oncol 2025;43(17 Suppl):LBA5006
Lorenzo, G. D., Montorsi, F., & Buonerba, C. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.06.006
A Podcast on Integrating Genetic Testing for Homologous Recombination Repair Gene Alterations in Patients with Prostate Cancer in the USA: a Multidisciplinary Approach to Overcoming the Obstacles
Szymaniak, B. M., Morgans, A. K., & Shore, N. D. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01159-z
Self-citation
Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis
Guo, X., Li, Y., Wang, M., Peng, H., Guo, H., Hou, T., Zhang, H., Jin, J., Sheng, T., Fan, Y., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003709
Reporting of Health-Related Quality of Life Outcome Measures in Genotype based Targeted Therapies for Advanced CancersPreprint
Liu, T. F. D., Kazmi, F., Barry, C., Mishra, S. R., Dahal, P. K., Katyal, R., & Shrestha, N. (2025) · Research Square · doi:10.21203/rs.3.rs-7091849/v1
PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer
Cunningham, M. L., Vasquez‐Gonzalez, J., Barnada, S. M., Tchotorlishvili, S., Jones, L., Maguire, R., Lewis, G., Rizwan, K., Deng, J., Koachar, S., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70098
The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC Receiving Talazoparib Plus Enzalutamide: A Podcast
Lloyd, J. L. E., & Batten, J. A. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00376-w
Improving Clinical Decisions Through Primary Trial Data Review—The Regulatory Lens
Jiang, N., Yang, Z., & Li, N. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3532
Therapiemanagement des mCRPC bei Kombinationen mit PARP-Inhibitoren in der klinischen Praxis
Retz, M. M., Borkowetz, A., Wittenzellner, K., Aga, H., & Amsberg, G. V. (2025) · Aktuelle Urologie · doi:10.1055/a-2669-8781
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study
Kloots, I. S. H., Slootbeek, P. H. J., Tolmeijer, S. H., van Wilpe, S., Smits, M., van Helvert, S., Kroeze, L. I., van Ipenburg, J. A., Grünberg, K., Kets, C. M., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03243-7
Self-citation
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Souza, A., Hadfield, M. J., Lu, S., Golijanin, D. J., Wood, R., Margolis, J. M., Anderson, K., Olszewski, A. J., Holder, S. L., El‐Deiry, W. S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0651
PARP-(Poly-Adenosindiphosphat-Ribose-Polymerase)Inhibitor-Kombinationstherapie beim metastasierten kastrationsresistenten Prostatakarzinom
Ohlmann, C., Gratzke, C., & Krabbe, L. (2025) · Die Urologie · doi:10.1007/s00120-025-02747-7
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial
McKenzie, J., & Azad, A. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.008
Restricted mean survival time comparison of olaparib plus abiraterone versus talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer: indirect analyses of propel and talapro-2
Yasuda, Y., Yoshida, S., Yajima, S., Sato, H., Hirakawa, A., & Fujii, Y. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04951-y
Reshaping Prostate Cancer Therapies with Biomarker-Driven Strategies
Thornber, K. (2025) · European Medical Journal · doi:10.33590/emj/hsit5578
Prognostic and Therapeutic Relevance of BRCA1/2 Zygosity in Prostate Cancer: A Multicohort Desk-Based AnalysisPreprint
Parawansa, A. M. R. P. B., Yaqin, M. A., & Murtadho, F. A. (2026) · medRxiv · doi:10.64898/2026.02.13.26346266
Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer
Ofner, H., Einspieler, H., Ozenil, M., Spielvogel, C. P., Langrate, I. K., Bamminger, K., Hassler, M. R., Baltzer, P., Shariat, S. F., Hacker, M., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.02.012
Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions
Shi, X., Rifai, S., Meher, Z., & Hussain, A. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001230
Talazoparib (Talzenna)
CDA-AMC (2026) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2026.1397
Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy
Calderón, E., Späth, M. S., Maas, M., la Fougère, C., & Trautwein, N. F. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006443
Aktualisierung S3-Leitlinie zum metastasierten Prostatakarzinom – Leitlinienempfehlungen und Expertenkonsens
Grimm, M., Gratzke, C., Hadaschik, B. A., Eiber, M., Herrmann, K., Hellmis, E., Klier, J., Kristiansen, G., Wiedemann, A., Merseburger, A. S., et al. (2026) · Die Urologie · doi:10.1007/s00120-026-02817-4
First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France
Dourthe, L. M., Guillot, A., Vassal, C., Kazan, E., Coeffic, D., Rebischung, C., Suau, D., Lahouegue, A., Aboulabbes, S., Falabregues, A., et al. (2026) · Drugs - Real World Outcomes · doi:10.1007/s40801-026-00551-z
Survival Outcomes Based on Line of Therapy and Treatment Trends With Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
Ostrowski, M., Jo, Y., Hardy, T., Gebrael, G., Srivastava, A., Özay, Z. İ., Chehade, C. H., Sayegh, N., Ji, R., Thomas, V. M., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00167
Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations
Castro, E., Wang, D., Paganelli, S., Haltner, A., Su, N., Kirker, M., Chang, J., & Samjoo, I. A. (2026) · The Oncologist · doi:10.1093/oncolo/oyag143
Management of CRPC (Metastatic and Non-metastatic)
Kashyap, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-5945-9_8
Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer
Sunada, T., Kamiyama, Y., Fujiwara, M., Hikami, K., Fukunaga, A., Fukui, T., Mizuno, K., Okasho, K., Kita, Y., Sumiyoshi, T., et al. (2026) · The Prostate · doi:10.1002/pros.70192
Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer
González‐Peramato, P., García‐Fernández, E., Jambrina, A., Salinas, J. F., Hernández‐Losa, J., Linares-Espinós, E., Rojo, F., Mateo, J., & Olmos, D. (2026) · Revista Española de Patología · doi:10.1016/j.patol.2026.100873
Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program
Caramelo, B., García-Berbel, P., Carmen, S. D., Terán, A. K. C., Corrêa, L., Martinez-Villaseñor, L., Sotelo, M., Rojo, F., Gómez‐Román, J., Durán, I., et al. (2026) · Cancers · doi:10.3390/cancers18101614
PSMA theranostics in the evolving landscape of metastatic prostate cancer: challenges and opportunities
Wang, X., Holler, S. D., & Hogan, T. F. (2026) · ONCOLOGIE · doi:10.1515/oncologie-2025-0571
Cell-free DNA in prostate cancer and treatment selection
McKendry, K., Maurice‐Dror, C., & Chi, K. N. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2688295
Advancing metastatic prostate cancer care: best practices and future directions in molecular testing
Castro, E., Chen, J., Lowentritt, B. H., Das, P. M., Dowlati, R., & Olmos, D. (2026) · Prostate International · doi:10.1016/j.prnil.2026.06.002

Authors: Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Virizuela, J. A., Emmenegger, U., Navratil, J., Buchschacher, G. L., Poehlein, C., Harrington, E. A., Desai, C., Kang, J., & Saad, F.
Affiliations: University of Manchester (GB)
Duke University (US)
Centre Hospitalier Universitaire de Besançon (FR)
Keio University (JP)
Carolina Urologic Research Center (US)
Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Hospital Nossa Senhora da Conceição (BR)
Hospital de Base (BR)
Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey
Radboud University Medical Center (NL)
Ashford Cancer Centre Research, Adelaide, South Australia
University Hospital Southampton NHS Foundation Trust (GB)
Centre Hospitalier de Cornouaille (FR)
National Cancer Center (KR)
Kagawa University Hospital (JP)
Hospital Universitario Virgen Macarena (ES)
Sunnybrook Research Institute (CA)
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Kaiser Permanente (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (United States) (US)
Centre Hospitalier de l’Universite de Montreal, Montreal
ORCID: Clarke, Noel W.
Armstrong, Andrew J.
Thiery-Vuillemin, Antoine
Oya, Mototsugu
Shore, Neal
Procopio, Giuseppe
Girotto, Gustavo
Mehra, Niven
Joung, Jae Y.
Sugimoto, Mikio
Virizuela, Juan A.
Emmenegger, Urban
Buchschacher, Gary L.
Poehlein, Christian
Harrington, Elizabeth A.
Kang, Jinyu
Venue: NEJM Evidence
Publisher: Massachusetts Medical Society
Published: 2022-08-23
Volume: 1
Issue: 9
Pages: EVIDoa2200043-EVIDoa2200043
ISSN: 2766-5526 (ISSN-L)
DOI: 10.1056/evidoa2200043
OpenAlex: W4281770555
Cited by: 426
References: 27
Citations by year: 2026: 77 · 2025: 108 · 2024: 111 · 2023: 110 · 2022: 20
FWCI: 56.30
Type: journal article
Language: en
Open access: closed
Locations: NEJM Evidence (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: abiraterone, olaparib, metastatic castration-resistant prostate cancer, PARP inhibitors, first-line therapy, homologous recombination deficiency, progression-free survival, overall survival, combination therapy, PARP inhibitor resistance, circulating tumor DNA, anemia, fatigue, nausea, hormone therapy
MeSH terms: Androstenes, Antineoplastic Combined Chemotherapy Protocols, Humans, Male, Phthalazines, Piperazines, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks